Galderma

Galderma, founded in 1981, is a pure-play dermatology company operating across approximately 90 countries. With a workforce of more than 7,000 employees, it develops and markets science-based solutions in three core areas: injectable aesthetics, dermatological skincare, and therapeutic dermatology. The company reported net sales of 4.410 billion USD in 2024, reflecting its scale within the global dermatology sector.

Operating a therapeutic dermatology division alongside its aesthetic product lines places Galderma within stringent regulatory frameworks across multiple jurisdictions. Its products, from prescription treatments to aesthetic injectables, are subject to the requirements of health authorities such as the FDA, EMA, and their equivalents in the roughly 90 markets where the company maintains a presence. The integrated nature of its dermatology strategy - spanning both medical and consumer-facing products - demands robust compliance infrastructure covering pharmacovigilance, advertising standards, and product registration.

Galderma's culture emphasises scientific rigour and close partnership with healthcare professionals, including a global aesthetic injector training network. This orientation toward clinical evidence and practitioner engagement means the company navigates complex regulatory environments not only at the product level but also in its professional education and promotional activities. For compliance professionals, the breadth of Galderma's operations - cutting across regulated therapeutic products and aesthetic treatments in dozens of markets - presents a landscape of varied and evolving regulatory obligations.